PHAR 408 Final Exam Answer Key

1. a) Antiestrogen or estrogen antagonest

b) LHRH agonist or gonadrotrophin – releasing hormone agonist

c) Aromatase inhibitor

2. 1). Both hydroxy groups are OK;

2). Nitrogen

3. a) Flutamide or Wilutamide or Bicalutamide or Megestrol or Cyproteron

b) LHRH agonist

4. a) Aromatase

b) P450

c) 3 nitrogen ring

5. b 6. c 7. True 8. True

9. Either of the following is correct:

1). Receptor down regulation. Trastuzumab binds to HER2 on the cell surface, the

complex is then internalized into the cell preventing HER2 from participating

in cell proliferation signaling.

2). Antibody-receptor cell-mediated cytotoxicity (ADCC). Patrolling natural killer

(NK) cells are attracted to the HER2 receptor complex cell. Eventually, the

cancer cell is consumed by the NK cells.

10. A “humanized” antibody is made by incorporating the (any of the following is

corrected: epitope binding, antigen biding, complementarity determining regions)

part of an animal antibody within the framework of a human antibody. This is

necessary since patients will eventually develop an immune response to the

foreign antibody rendering them ineffective.

11. Receptor type Function in Retinoid Action

Cellular Storage reservoirs

Nuclear Transcription activation

12. c 13. d 14. b 15. b 16. c 17. d

18. d 19. b 20. a 21. b 22. c 23. a

24. b 25. b 26. b 27. c 28. a 29. c

30. b 31. c 32. d

33. Cancer chemotherapy generally involves agents that can inhibit the growth of

tumors whereas cancer chemoprevention involves agents that block the process

of carcinogenesis

34. Crude materials such as plant extracts are tested for activity with an in vitro assay,

and then successive fractions are produced by methods such as chromatograpy.

Each fraction is tested, and active fractions are further separated until pure active

Chemicals are obtained. (a flow chart may be presented rather than a written

Description)

35. False